Energy-Efficient Inexact Speculative Adder with High Performance and Accuracy Control

Inexact and approximate circuit design is a promising approach to improve performance and energy efficiency in technology-scaled and low-power digital systems. Such strategy is suitable for error-tolerant applications involving perceptive or statistical outputs. This paper presents a novel architecture of an Inexact Speculative Adder with optimized hardware efficiency and advanced compensation technique with either error correction or error reduction. This general topology of speculative adders improves performance and enables precise accuracy control. A brief design methodology and comparative study of this speculative adder are also presented herein, demonstrating power savings up to 26 % and energy-delay-area reductions up to 60% at equivalent accuracy compared to the state-of-the-art

Hardware Acceleration of HDR-Image Tone Mapping on an FPGA-CPU Platform Through High-Level Synthesis

In this paper, the hardware acceleration of a tone-mapping algorithm for High-Dynamic-Range image processing is presented. Starting from the C++ source code, High-Level Synthesis has been performed using Xilinx SDSoC for a Xilinx Zynq SoC device. After an initial code optimization to improve the memory access bottleneck, SDSoC pragmas have been introduced to boost system performance through an increased parallelism. Preliminary results have shown significant reductions in the execution time and the energy consumption compared to the conventional software implementation

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach

Background: Teprotumumab is the first treatment for thyroid eye disease (TED), a debilitating autoinflammatory condition, approved by the Food and Drug Administration in the United States, which reduces proptosis and improves quality of life. In the absence of guidelines, clinical recommendations were developed for using teprotumumab in patients with TED in the United States. Methods: A 3-round modified-Delphi panel was conducted between October 2020 and February 2021 with experts in the management of patients with TED. Key areas regarding the use of teprotumumab were investigated, including eligible patient populations, concomitant treatments, and assessment of response and adverse events. This used 2 survey rounds via an online questionnaire, where statements were scored using 9-point Likert scales. Statements with conflict were included in the third round, involving a consensus meeting via videoconference. Results: Consensus was obtained for all statements (n = 75); of which, 56% were revised to enable agreement of the group. The consensus meeting provided agreement regarding which populations should receive teprotumumab therapy, including all adult patients with TED with a clinical activity score of ≥4. Treatment with teprotumumab can also be considered for TED patients displaying the following characteristics: a CAS of <3, lid retraction of ≥2, and mild or early optic neuropathy with close clinical observation. Further recommendations included suitability of treatment for those beyond 16 months following the initial diagnosis of TED, low CAS concomitant treatment with steroids in some cases, retreatment for those who have relapses, and finally a recommendation to continue therapy for all 8 infusions despite the lack of response by the fourth infusion. Conclusions: This work constitutes the first consensus on guidelines for the use of teprotumumab. The modified Delphi approach involved physicians with significant experience with the clinical use of teprotumumab, and recommendations were based on current evidence

A FRET Sensor for Non-Invasive Imaging of Amyloid Formation in Vivo

Kaminski Schierle GS, Bertoncini CW, Chan FTS, et al. A FRET Sensor for Non-Invasive Imaging of Amyloid Formation in Vivo. ChemPhysChem. 2011;12(3):673-680.Misfolding and aggregation of amyloidogenic polypeptides lie at the root of many neurodegenerative diseases. Whilst protein aggregation can be readily studied in vitro by established biophysical techniques, direct observation of the nature and kinetics of aggregation processes taking place in vivo is much more challenging. We describe here, however, a Forster resonance energy transfer sensor that permits the aggregation kinetics of amyloidogenic proteins to be quantified in living systems by exploiting our observation that amyloid assemblies can act as energy acceptors for variants of fluorescent proteins. The observed lifetime reduction can be attributed to fluorescence energy transfer to intrinsic energy states associated with the growing amyloid species. Indeed, for alpha-synuclein, a protein whose aggregation is linked to Parkinson's disease, we have used this sensor to follow the kinetics of the self-association reactions taking place in vitro and in vivo and to reveal the nature of the ensuing aggregated species. Experiments were conducted in vitro, in cells in culture and in living Caenorhabditis elegans. For the latter the readout correlates directly with the appearance of a toxic phenotype. The ability to measure the appearance and development of pathogenic amyloid species in a living animal and the ability to relate such data to similar processes observed in vitro provides a powerful new tool in the study of the pathology of the family of misfolding disorders. Our study confirms the importance of the molecular environment in which aggregation reactions take place, highlighting similarities as well as differences between the processes occurring in vitro and in vivo, and their significance for defining the molecular physiology of the diseases with which they are associated